Antitumor therapeutic effects of a genetically engineered Salmonella typhimurium harboring TNF-α in mice

Won Suck Yoon, Yang Seok Chae, Juyeon Hong, Yong Keun Park

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Although the use of TNF-α in the treatment of cancer is restricted due to its non-specific cytotoxicity and narrow range of applications to different cancers in clinical trials, we investigated a safe anti-cancer drug by the use of engineered bacterial capsule harboring TNF-α. The engineered bacterial capsule was designed to target cancer cells, promote a tumor-suppressive environment, and increase the efficacy of existing cancer treatments, including chemotherapy, radiotherapy, and cell therapy. The engineered bacterial capsule was constructed with Salmonella capsulizing TNF-α protein, which was produced and capsulized by Salmonella to reduce side effects of the protein. This bacterial capsule induced a tumor-suppressive environment through the activation of natural killer cells. Engineered bacterial capsule invaded tumor cells, released TNF-α, and induced apoptosis of tumor cells without apparent side effects. In a murine melanoma model, the bacterial capsule of TNF-α significantly inhibited tumor growth by 80-100% and prolonged the survival of the mice. When tested in combination with chemotherapy (cisplatin), antibiotics, and vaccine, recombinant microbial treatment increased the anti-tumor effects of existing therapies. The anti-tumor effects of the bacterial capsule of TNF-α were also observed in cervical cancer, melanoma, breast cancer, colon cancer, and renal carcinoma. These results suggest that the bacterial capsule of TNF-α is a promising strategy for TNF-α treatment.

Original languageEnglish
Pages (from-to)1807-1819
Number of pages13
JournalApplied Microbiology and Biotechnology
Volume89
Issue number6
DOIs
Publication statusPublished - 2011 Mar 1

Fingerprint

Bacterial Capsules
Therapeutic Uses
Salmonella typhimurium
Neoplasms
Salmonella
Colonic Neoplasms
Melanoma
Breast Neoplasms
Therapeutics
Synthetic Vaccines
Cell- and Tissue-Based Therapy
Combination Drug Therapy
Uterine Cervical Neoplasms
Natural Killer Cells
Cisplatin
Proteins
Radiotherapy
Clinical Trials

Keywords

  • Antitumor effects
  • Salmonella typhimurium
  • TNF-α
  • Tumor treatments

ASJC Scopus subject areas

  • Biotechnology
  • Applied Microbiology and Biotechnology

Cite this

Antitumor therapeutic effects of a genetically engineered Salmonella typhimurium harboring TNF-α in mice. / Yoon, Won Suck; Chae, Yang Seok; Hong, Juyeon; Park, Yong Keun.

In: Applied Microbiology and Biotechnology, Vol. 89, No. 6, 01.03.2011, p. 1807-1819.

Research output: Contribution to journalArticle

@article{0e028c386c084a81b804e0254698a298,
title = "Antitumor therapeutic effects of a genetically engineered Salmonella typhimurium harboring TNF-α in mice",
abstract = "Although the use of TNF-α in the treatment of cancer is restricted due to its non-specific cytotoxicity and narrow range of applications to different cancers in clinical trials, we investigated a safe anti-cancer drug by the use of engineered bacterial capsule harboring TNF-α. The engineered bacterial capsule was designed to target cancer cells, promote a tumor-suppressive environment, and increase the efficacy of existing cancer treatments, including chemotherapy, radiotherapy, and cell therapy. The engineered bacterial capsule was constructed with Salmonella capsulizing TNF-α protein, which was produced and capsulized by Salmonella to reduce side effects of the protein. This bacterial capsule induced a tumor-suppressive environment through the activation of natural killer cells. Engineered bacterial capsule invaded tumor cells, released TNF-α, and induced apoptosis of tumor cells without apparent side effects. In a murine melanoma model, the bacterial capsule of TNF-α significantly inhibited tumor growth by 80-100{\%} and prolonged the survival of the mice. When tested in combination with chemotherapy (cisplatin), antibiotics, and vaccine, recombinant microbial treatment increased the anti-tumor effects of existing therapies. The anti-tumor effects of the bacterial capsule of TNF-α were also observed in cervical cancer, melanoma, breast cancer, colon cancer, and renal carcinoma. These results suggest that the bacterial capsule of TNF-α is a promising strategy for TNF-α treatment.",
keywords = "Antitumor effects, Salmonella typhimurium, TNF-α, Tumor treatments",
author = "Yoon, {Won Suck} and Chae, {Yang Seok} and Juyeon Hong and Park, {Yong Keun}",
year = "2011",
month = "3",
day = "1",
doi = "10.1007/s00253-010-3006-4",
language = "English",
volume = "89",
pages = "1807--1819",
journal = "Applied Microbiology and Biotechnology",
issn = "0175-7598",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Antitumor therapeutic effects of a genetically engineered Salmonella typhimurium harboring TNF-α in mice

AU - Yoon, Won Suck

AU - Chae, Yang Seok

AU - Hong, Juyeon

AU - Park, Yong Keun

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Although the use of TNF-α in the treatment of cancer is restricted due to its non-specific cytotoxicity and narrow range of applications to different cancers in clinical trials, we investigated a safe anti-cancer drug by the use of engineered bacterial capsule harboring TNF-α. The engineered bacterial capsule was designed to target cancer cells, promote a tumor-suppressive environment, and increase the efficacy of existing cancer treatments, including chemotherapy, radiotherapy, and cell therapy. The engineered bacterial capsule was constructed with Salmonella capsulizing TNF-α protein, which was produced and capsulized by Salmonella to reduce side effects of the protein. This bacterial capsule induced a tumor-suppressive environment through the activation of natural killer cells. Engineered bacterial capsule invaded tumor cells, released TNF-α, and induced apoptosis of tumor cells without apparent side effects. In a murine melanoma model, the bacterial capsule of TNF-α significantly inhibited tumor growth by 80-100% and prolonged the survival of the mice. When tested in combination with chemotherapy (cisplatin), antibiotics, and vaccine, recombinant microbial treatment increased the anti-tumor effects of existing therapies. The anti-tumor effects of the bacterial capsule of TNF-α were also observed in cervical cancer, melanoma, breast cancer, colon cancer, and renal carcinoma. These results suggest that the bacterial capsule of TNF-α is a promising strategy for TNF-α treatment.

AB - Although the use of TNF-α in the treatment of cancer is restricted due to its non-specific cytotoxicity and narrow range of applications to different cancers in clinical trials, we investigated a safe anti-cancer drug by the use of engineered bacterial capsule harboring TNF-α. The engineered bacterial capsule was designed to target cancer cells, promote a tumor-suppressive environment, and increase the efficacy of existing cancer treatments, including chemotherapy, radiotherapy, and cell therapy. The engineered bacterial capsule was constructed with Salmonella capsulizing TNF-α protein, which was produced and capsulized by Salmonella to reduce side effects of the protein. This bacterial capsule induced a tumor-suppressive environment through the activation of natural killer cells. Engineered bacterial capsule invaded tumor cells, released TNF-α, and induced apoptosis of tumor cells without apparent side effects. In a murine melanoma model, the bacterial capsule of TNF-α significantly inhibited tumor growth by 80-100% and prolonged the survival of the mice. When tested in combination with chemotherapy (cisplatin), antibiotics, and vaccine, recombinant microbial treatment increased the anti-tumor effects of existing therapies. The anti-tumor effects of the bacterial capsule of TNF-α were also observed in cervical cancer, melanoma, breast cancer, colon cancer, and renal carcinoma. These results suggest that the bacterial capsule of TNF-α is a promising strategy for TNF-α treatment.

KW - Antitumor effects

KW - Salmonella typhimurium

KW - TNF-α

KW - Tumor treatments

UR - http://www.scopus.com/inward/record.url?scp=79952575222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952575222&partnerID=8YFLogxK

U2 - 10.1007/s00253-010-3006-4

DO - 10.1007/s00253-010-3006-4

M3 - Article

VL - 89

SP - 1807

EP - 1819

JO - Applied Microbiology and Biotechnology

JF - Applied Microbiology and Biotechnology

SN - 0175-7598

IS - 6

ER -